简介内容:Lanraplenib is a highly selective and orally active SYK inhibitor (IC50= nM) in development for the treatment of inflammatory diseases. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding t